Area of research
Infectious Diseases · Molecular Biology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, SARS-CoV-2 detection and testing, and RNA modifications and cancer.
Improved Resolution of Influenza Vaccination Responses With High-Throughput Live Virus Microneutralisation.
Impact of first SARS-CoV-2 infection variant on serological responses against Omicron: findings from the SIREN study
SARS-CoV-2 envelope protein induces LC3 lipidation via the V-ATPase-ATG16L1 axis
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial
Optimizing warfarin dosing for patients with atrial fibrillation using machine learning
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes.
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.
CD4+ and CD8+ T cell and antibody correlates of protection against Delta vaccine breakthrough infection: A nested case-control study within the PITCH study
Examining the association of live virus neutralisation activity of capillary microsamples and risk of SARS-CoV-2 infections: a nested case control study within the Virus Watch community cohort
Dichotomy of neutralizing antibody, B cell and T cell responses to SARS-CoV-2 vaccination and protection in healthy adults
SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies.
Microbial communities form rich extracellular metabolomes that foster metabolic interactions and promote drug tolerance.
USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer.
Three-dose vaccination elicits neutralising antibodies against omicron.
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study
WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.
Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Functional profiling of long intergenic non-coding RNAs in fission yeast.
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Correction: Functional profiling of long intergenic non-coding RNAs in fission yeast.
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.